Akebia Therapeutics, Inc.
AKBA · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Market Cap | $401 | $232 | $105 | $375 |
| - Cash | $52 | $43 | $90 | $150 |
| + Debt | $48 | $104 | $100 | $136 |
| Enterprise Value | $397 | $294 | $115 | $361 |
| Revenue | $160 | $195 | $292 | $212 |
| % Growth | -17.7% | -33.5% | 38.2% | – |
| Gross Profit | $97 | $120 | $270 | $130 |
| % Margin | 60.6% | 61.9% | 92.3% | 61.5% |
| EBITDA | -$14 | -$8 | $3 | -$190 |
| % Margin | -8.6% | -4.2% | 1% | -89.7% |
| Net Income | -$69 | -$52 | -$94 | -$282 |
| % Margin | -43.3% | -26.7% | -32.2% | -133.3% |
| EPS Diluted | -0.33 | -0.28 | -0.58 | -1.48 |
| % Growth | -17.9% | 51.7% | 60.8% | – |
| Operating Cash Flow | -$41 | -$23 | -$73 | -$253 |
| Capital Expenditures | -$0 | $0 | -$0 | -$0 |
| Free Cash Flow | -$41 | -$23 | -$73 | -$253 |